


Affidea Enters an Agreement to Acquire the Cancer Care Group Nu-Med in Poland



Affidea Group, the pan-European provider of specialist healthcare services, including cancer care, advanced diagnostic imaging and community-based polyclinics, announced today that it has entered into a binding agreement to acquire Nu-Med, a renowned cancer care provider in Poland.

• The deal is subject to approval by the Polish Office of Competition and Consumer Protection.

Nu-Med is an established cancer care provider which operates four medical centres across Poland: Elblag (North), Katowice (South), Tomaszów Mazowiecki (centre), and Zamość (East). In addition, Nu-Med runs four walk-in outpatient clinics in Bełchatów, Działdowo, Iława and Ostróda. The company is recognised for high-quality clinical standards in comprehensive oncology services: radiotherapy, brachytherapy, chemotherapy, oncology consultations, advanced diagnostics and daily hospitalisation.



The acquisition complements Affidea's existing cancer care portfolio in Poland and will allow the two companies to further improve Patient Access to integrated cancer services, including prevention, supporting early diagnosis and cancer treatment in a comprehensive and coordinated manner. In Poland, cancer is the second most frequent cause of death, with more than 170,000 new cases detected and 100,000 deaths annually. Natural incidence is targeted to increase new cases to 230,000 by 2030.



Guy Blomfield, Affidea Group CEO and Chairman of the Management Board, commented: "Affidea has a strong commitment to expanding access to high-quality cancer care services in the communities we serve across Europe—highlighted by recent acquisitions including MedEuropa in Romania and Brust Zentrum Zurich in Switzerland. Poland's Health Policy is committed to improving cancer survivorship outcomes, and the acquisition of Nu-Med enhances Affidea's role in working in partnership with the NFZ to enhance Patient Access to integrated cancer care services. I very much welcome Nu-Med's reputable medical, management and administrative team to the Affidea community and look forward to building upon our already strong foundation of care, ensuring that patients across the country continue to receive the highest standards of care. Together, Affidea and Nu-Med share a commitment to clinical excellence, and this partnership will play an important role in improving early detection, diagnosis, and access to cutting-edge radiotherapy services in community settings throughout Poland."

Mesut Göral, President of the Management Board and CEO of Affidea Poland, Senior Vice President and COO for Affidea Group, commented: "This important and sizable acquisition highlights Affidea's commitment to supporting the National Oncology Strategy, ensuring better patient access to top-quality services for cancer prevention, early diagnosis, and treatment, in a comprehensive and integrated manner. Nu-Med's renowned radiotherapy centres, led by their Senior Leadership Team and highly qualified clinical and non-clinical colleagues, perfectly complement Affidea's operations and culture. We very much look forward to working together in our common mission of improving cancer care outcomes and service excellence."



Michał Rusiecki, El's managing partner responsible for the investment, said: "This exit represents a significant milestone both in Nu-Med's growth and in El's investment strategy in the healthcare sector, underscoring the firm's commitment to creating value in this important sector. We are extremely proud that, during our investment period, we provided critical care to almost 70,000 patients." He added: "From a single radiotherapy centre, we've grown Nu-Med into a leading provider of cancer care. The sale to Affidea ensures that Nu-Med will continue providing high-quality, comprehensive cancer care to patients across Poland as part of a premier international organisation."

Completion of the acquisition is subject to the approval of the Polish Office of Competition and Consumer Protection. Affidea Group was advised by WKB Lawyers on legal, EY on financial and tax due diligence and by VCP Polska on M&A investment banking services. The Sellers were advised by Gide Loyrette Nouel on legal, BNP Paribas on M&A investment banking, A.T. Kearney on commercial and Deloitte on financial and tax services.



Source & Image Credit: Affidea

Published on: Tue, 20 Aug 2024